<scp>Cancer‐Specific</scp> health equity metrics in the United States of America: A scoping review

Starkweather, Angela; Cohen, Bevin; Gray, Tamryn F.; Linder, Lauri; Zanville, Noah

doi:10.1002/cam4.5881

Cited by 2 publications

(2 citation statements)

References 66 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Differences between healthcare providers have been observed previously both regarding implementation of treatments and outcome of cancer care [31,32], and hospital-level variability in guideline adherence has translated into effects on overall survival [33,34]. Some factors that have previously been associated with non-adherence to treatment guidelines are access to cancer specialists [31], facility patient volume [35], social determinants [36] and cost of care [37]. We argue that assessments in the regions of cost/benefit ratio had a strong impact on adherence since the cost for doublet therapy is carried by each region.…”

Section: Discussionmentioning

confidence: 91%

“…The specific reason for the low adherence and the large differences between regions in our study cannot be deduced from our data. Differences between healthcare providers have been observed previously both regarding implementation of treatments and outcome of cancer care [31,32], and hospital-level variability in guideline adherence has translated into effects on overall survival [33,34]. Some factors that have previously been associated with non-adherence to treatment guidelines are access to cancer specialists [31], facility patient volume [35], social determinants [36] and cost of care [37].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Uptake of doublet therapy for de novo metastatic castration sensitive prostate cancer: a population-based drug utilisation study in Sweden

Gedeborg,

Sandin,

Thellenberg-Karlsson

et al. 2023

SJU

View full text Add to dashboard Cite

Background: Randomised controlled trials have demonstrated prolonged survival with new upfront treatments in addition to standard androgen deprivation therapy (ADT) in men with de novo metastatic castration-sensitive prostate cancer. We describe patient characteristics, time trends and regional differences in uptake of these new treatment strategies in clinical practice. Material and methods: This descriptive study consisted of men registered in the National Prostate Cancer Register of Sweden from 1 January 2018 to 31 March 2022 with de novo metastatic castration-sensitive prostate cancer defined by the presence of metastases on imaging at the time of diagnosis. Life expectancy was calculated based on age, Charlson Comorbidity Index and a Drug Comorbidity Index. Results: Within 6 months from diagnosis, 57% (1,677/2,959) of men with de novo metastatic castration-sensitive prostate cancer and more than 3 years of life expectancy had received docetaxel, abiraterone, enzalutamide, apalutamide and/or radiotherapy. Over time, there was a 2-fold increase in uptake of any added treatment, mainly driven by a 6-fold increase in use of abiraterone, enzalutamide or apalutamide, with little change in use of other treatments. Conclusions: Slightly more than half of men diagnosed with de novo metastatic castration-sensitive prostate cancer and a life expectancy of at least 3 years received additions to standard ADT as recommended by national guidelines in 2019–2022 in Sweden. There was a 2-fold increase in use of these treatments during the study period; however, efforts to further increase adherence to guidelines are warranted.

show abstract